文献速递脑血管病

颈动脉狭窄与复发性缺血性卒中:POINT试验事后分析

Carotid Stenosis and Recurrent Ischemic Stroke: A Post-Hoc Analysis of the POINT Trial.
PubMed 文献 · Stroke · 2021-05-04

POINT试验事后分析纳入3941例轻型缺血性卒中或高危TIA患者,评估≥50%颈动脉狭窄与缺血性卒中风险的关系及氯吡格雷疗效的修饰作用。调整后≥50%狭窄与缺血性卒中风险相关(HR 2.45,95%CI 1.68-3.57,P<0.001);氯吡格雷疗效在狭窄组与无狭窄组间无显著差异(交互P=0.573)。

要点

  • ≥50%颈动脉狭窄与随访期缺血性卒中风险独立相关(HR 2.45)。
  • 氯吡格雷联合阿司匹林的疗效不受≥50%颈动脉狭窄显著修饰。
  • 狭窄组与无狭窄组的氯吡格雷效应无统计学交互(P=0.573)。

核心结论

  • ≥50%颈动脉狭窄与随访期缺血性卒中风险增加相关。
  • 加用氯吡格雷的疗效在有无颈动脉狭窄患者间无显著差异。

研究设计与样本

  • POINT试验(NCT03354429)事后分析,随机对照试验。
  • 纳入4881例中符合标准的3941例轻型缺血性卒中或高危TIA患者。
  • 随机接受氯吡格雷加阿司匹林或单用阿司匹林,末次正常后12小时内入组。

主要发现

  • 调整模型中≥50%颈动脉狭窄与缺血性卒中风险相关(HR 2.45,95%CI 1.68-3.57,P<0.001)。
  • 狭窄<50%者氯吡格雷调整HR 0.68(95%CI 0.50-0.93,P=0.014)。
  • 狭窄≥50%者氯吡格雷调整HR 0.88(95%CI 0.45-1.72,P=0.703)。
  • 狭窄状态与氯吡格雷疗效的交互P=0.573。

关键数值与推荐

  • 主要预测因素为任一侧颈内动脉≥50%狭窄。
  • 主要结局为缺血性卒中。
  • 采用Cox回归模型分析关联及效应修饰。

临床怎么用

  • 对轻型缺血性卒中或高危TIA患者应评估颈动脉狭窄以分层卒中风险。
  • ≥50%颈动脉狭窄提示缺血性卒中风险较高,但不应据此预期氯吡格雷获益更大。

局限性

  • 为事后分析,结果需谨慎解读。
  • 原文未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Randomized trials demonstrated the benefit of dual antiplatelet therapy in patients with minor ischemic stroke or high-risk transient ischemic attack. We sought to determine whether the presence of carotid stenosis was associated with increased risk of ischemic stroke and whether the addition of clopidogrel to aspirin was associated with more benefit in patients with versus without carotid stenosis. METHODS: This is a post-hoc analysis of the POINT trial (Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke) that randomized patients with minor ischemic stroke or high-risk transient ischemic attack within 12 hours from last known normal to receive either clopidogrel plus aspirin or aspirin alone. The primary predictor was the presence of ≥50% stenosis in either cervical internal carotid artery. The primary outcome was ischemic stroke. We built Cox regression models to determine the association between carotid stenosis and ischemic stroke and whether the effect of clopidogrel was modified by ≥50% carotid stenosis. RESULTS: Among 4881 patients enrolled POINT, 3941 patients met the inclusion criteria. In adjusted models, ≥50% carotid stenosis was associated with ischemic stroke risk (hazard ratio, 2.45 [95% CI, 1.68-3.57], P<0.001). The effect of clopidogrel (versus placebo) on ischemic stroke risk was not significantly different in patients with <50% carotid stenosis (adjusted hazard ratio, 0.68 [95% CI, 0.50-0.93], P=0.014) versus those with ≥50% carotid stenosis (adjusted hazard ratio, 0.88 [95% CI, 0.45-1.72], P=0.703), P value for interaction=0.573. CONCLUSIONS: The presence of carotid stenosis was associated with increased risk of ischemic stroke during follow-up. The effect of added clopidogrel was not significantly different in patients with versus without carotid stenosis. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03354429.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Yaghi S, de Havenon A, Rostanski S, et al. Carotid Stenosis and Recurrent Ischemic Stroke: A Post-Hoc Analysis of the POINT Trial. Stroke. 2021. PMID: 33940954. doi:10.1161/STROKEAHA.121.034089

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。